A Study to Assess the Effectiveness and Safety of 2 Dosage Regimens of Oral Fidrisertib (IPN60130) for the Treatment of Fibrodysplasia Ossificans Progressiva (FOP).
Terminated · Phase 2 · NCT05039515
Conditions: Fibrodysplasia Ossificans Progressiva
At a glance
- Research payments reported, 2025
- $2.5M
- U.S. investigators named
- 10
- Sites paid
- 7
- Planned or actual enrollment
- 113
About the trial
- Sponsor
- Clementia Pharmaceuticals Inc. (with Ipsen)
- Tested
- IPN60130 (drug), IPN60130 (drug), Placebo (drug)
- Dates
- Started 2021-12-01; completion 2026-03-27
- Results posted
- Not yet
Fibrodysplasia Ossificans Progressiva (FOP) is a rare, severely disabling disease characterized by the presence of bone in soft tissue where bone normally does not exist, known as Heterotopic Ossification (HO). It is often associated with painful, recurrent episodes of soft tissue swelling (flare-ups) that lead to abnormal stiffening and immobility (ankyloses) of major joints with cumulative and irreversible loss of movement and disability. This study will evaluate the efficacy of 2 dosing regimens of IPN60130 in inhibiting new HO volume compared with placebo (a dummy treatment) in adult and paediatric participants with FOP. It will be assessed by a scan (provides internal images of the b…
From ClinicalTrials.gov, last updated 2026-04-24. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Ipsen Innovation reported $2.5M in research payments for this study in 2025 (293 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Harika Tirumani, MD Student in an Organized Health Care Education/Training Program · Little Rock, AR
- Edward C. Hsiao, M.D., PH.D. Endocrinology & Diabetes · San Francisco, CA
- Jamie T. Caracciolo, MD, MBA Radiology · Tampa, FL
- Tony T. Wong, M.D. Radiology · Winter Park, FL
- Randheer Shailam, MD Radiology · Boston, MA
- Robert J. Pignolo, MD Internal Medicine · Rochester, MN
- Eric Bogner, M.D. Radiology · New York, NY
- Mona Al Mukaddam, MD Endocrinology & Diabetes · Philadelphia, PA
- Viviane Khoury, MD Orthopedic Surgery · Philadelphia, PA
- Edna Mancilla, MD Pediatric Endocrinology · Philadelphia, PA
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- UCSF Langley Porter Psychiatric Hospital and Clinics, CA $1.0M
- $377,550
- Hospital of Univ of Pennsylvania, PA $361,320
- Mayo Clinic $223,121
- Gi Reviewers LLC $180,780
- Children's Hospital of Philadelphia, PA $172,147
- Scientia Imaging LLC $122,200
- Massachusetts General Physicians Organization $30,800
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.